IL-2: The First Effective Immunotherapy for Human Cancer
暂无分享,去创建一个
[1] B. Shalmon,et al. Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma: Intent-to-Treat Analysis and Efficacy after Failure to Prior Immunotherapies , 2013, Clinical Cancer Research.
[2] Jimmy Lin,et al. Mining Exomic Sequencing Data to Identify Mutated Antigens Recognized by Adoptively Transferred Tumor-reactive T cells , 2013, Nature Medicine.
[3] S. Rosenberg,et al. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors , 2013, Nature Reviews Clinical Oncology.
[4] K. Kinzler,et al. Cancer Genome Landscapes , 2013, Science.
[5] Jeffrey E. Lee,et al. Specific Lymphocyte Subsets Predict Response to Adoptive Cell Therapy Using Expanded Autologous Tumor-Infiltrating Lymphocytes in Metastatic Melanoma Patients , 2012, Clinical Cancer Research.
[6] V. Sondak,et al. Efficacy of Adoptive Cell Transfer of Tumor-infiltrating Lymphocytes After Lymphopenia Induction for Metastatic Melanoma , 2012, Journal of immunotherapy.
[7] S. Steinberg,et al. Levels of peripheral CD4(+)FoxP3(+) regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer. , 2012, Blood.
[8] S. Rosenberg,et al. CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic Melanoma , 2012, Clinical Cancer Research.
[9] Steven A. Rosenberg,et al. Cell transfer immunotherapy for metastatic solid cancer—what clinicians need to know , 2011, Nature Reviews Clinical Oncology.
[10] S. Steinberg,et al. Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy , 2011, Clinical Cancer Research.
[11] M. Merino,et al. T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.
[12] M. Raffeld,et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] W. Wilson,et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. , 2010, Blood.
[14] G. Trinchieri,et al. Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts. , 2010, Cancer research.
[15] S. Rosenberg,et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.
[16] S. Rosenberg,et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. , 2009, Blood.
[17] S. Rosenberg,et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] S. Steinberg,et al. High‐dose interleukin‐2 for the treatment of metastatic renal cell carcinoma , 2008, Cancer.
[19] S. Rosenberg,et al. Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes , 2006, Science.
[20] S. Rosenberg,et al. Adoptive immunotherapy for cancer: building on success , 2006, Nature Reviews Immunology.
[21] S. Rosenberg,et al. Cancer immunotherapy: moving beyond current vaccines , 2004, Nature Medicine.
[22] S. Steinberg,et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] M. Raffeld,et al. Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes , 2002, Science.
[24] F. Marincola,et al. A Phase I Study of Nonmyeloablative Chemotherapy and Adoptive Transfer of Autologous Tumor Antigen-Specific T Lymphocytes in Patients With Metastatic Melanoma , 2002, Journal of immunotherapy.
[25] F. Marincola,et al. Adoptive Transfer of Cloned Melanoma-Reactive T Lymphocytes for the Treatment of Patients with Metastatic Melanoma , 2001, Journal of immunotherapy.
[26] R. Fisher,et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] S. Steinberg,et al. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. , 1998, Annals of surgery.
[28] S. Rosenberg,et al. Trends in the safety of high dose bolus interleukin‐2 administration in patients with metastatic cancer , 1998, Cancer.
[29] R. Wiltrout,et al. Immune Responses To Metastases , 1996 .
[30] R. Fisher,et al. Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] S. Rosenberg,et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. , 1994, Journal of the National Cancer Institute.
[32] K. Sakaguchi,et al. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[33] S. Steinberg,et al. In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] S. Rosenberg,et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[35] S. Rosenberg,et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. , 1994, JAMA.
[36] S. Steinberg,et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. , 1993, Journal of the National Cancer Institute.
[37] N. Barth,et al. HIGH DOSE CONTINUOUS INFUSION INTERLEUKIN-2 IN 788 CANCER PATIENTS: THE NATIONAL BIOTHERAPY STUDY GROUP EXPERIENCE , 1992 .
[38] S. Rosenberg,et al. The use of interleukin-2 and lymphokine-activated killer cells for the treatment of patients with non-Hodgkin's lymphoma. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] K. Cornetta,et al. Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. , 1990, The New England journal of medicine.
[40] M. Atkins,et al. An acquired chemotactic defect in neutrophils from patients receiving interleukin-2 immunotherapy. , 1990, The New England journal of medicine.
[41] G. Semenzato. Lymphokine activated killer cells: a new approach to immunotherapy of cancer. , 1990, Leukemia.
[42] M. Lotze,et al. A prospective randomized trial evaluating prophylactic antibiotics to prevent triple-lumen catheter-related sepsis in patients treated with immunotherapy. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] S. Rosenberg,et al. In vivo distribution of adoptively transferred indium-111-labeled tumor infiltrating lymphocytes and peripheral blood lymphocytes in patients with metastatic melanoma. , 1989, Journal of the National Cancer Institute.
[44] S M Larson,et al. Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] S. Rosenberg,et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. , 1988, The New England journal of medicine.
[46] W. Linehan,et al. Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[47] S. Rosenberg,et al. Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. , 1987, Journal of immunological methods.
[48] W. M. Linehan,et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. , 1987, The New England journal of medicine.
[49] S. Rosenberg,et al. Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. , 1987, Journal of immunology.
[50] A. Chang,et al. High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity, and histologic findings. , 1986, JAMA.
[51] S. Rosenberg,et al. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. , 1986, Science.
[52] S. Rosenberg,et al. Murine lymphokine-activated killer (LAK) cells: phenotypic characterization of the precursor and effector cells. , 1986, Journal of immunology.
[53] S. Rosenberg,et al. Immunotherapy of murine sarcomas using lymphokine activated killer cells: optimization of the schedule and route of administration of recombinant interleukin-2. , 1986, Cancer research.
[54] A. Chang,et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. , 1985, The New England journal of medicine.
[55] S. Rosenberg,et al. In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. , 1985, Journal of immunology.
[56] S. Rosenberg,et al. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2 , 1985, The Journal of experimental medicine.
[57] S. Rosenberg,et al. Successful therapy of hepatic metastases from several murine tumors using lymphokine-activated killer cells and recombinant interleukin-2 , 1985 .
[58] S. Rosenberg,et al. In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2. , 1985, Journal of immunology.
[59] M. Doyle,et al. Biological activity of recombinant human interleukin-2 produced in Escherichia coli. , 1984, Science.
[60] V. Chowdhry,et al. Purification and partial sequence analysis of human T-cell growth factor. , 1983, Proceedings of the National Academy of Sciences of the United States of America.
[61] Jan Tavernier,et al. Molecular cloning of human interleukin 2 cDNA and its expression in E. coli , 1983, Nucleic Acids Res..
[62] T. Taniguchi,et al. Structure and expression of a cloned cDNA for human interleukin-2 , 1983, Nature.
[63] S. Rosenberg,et al. Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells , 1983, The Journal of experimental medicine.
[64] T. Eberlein,et al. Regression of a disseminated syngeneic solid tumor by systemic transfer of lymphoid cells expanded in interleukin 2. , 1982, The Journal of experimental medicine.
[65] S. Rosenberg,et al. Lymphokine-activated killer cell phenomenon. Lysis of natural killer- resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes , 1982, The Journal of experimental medicine.
[66] P. Greenberg,et al. Eradication of disseminated murine leukemia by chemoimmunotherapy with cyclophosphamide and adoptively transferred immune syngeneic Lyt-1+2- lymphocytes , 1981, The Journal of experimental medicine.
[67] T. Eberlein,et al. In vitro growth of murine T cells. VI. Accelerated skin graft rejection caused by adoptively transferred cells expanded in T cell growth factor. , 1981, Journal of immunology.
[68] S. Rosenberg,et al. In vitro growth of cytotoxic human lymphocytes. III. The preparation of lectin-free T cell growth factor (TCGF) and an analysis of its activity. , 1981, Journal of immunology.
[69] P. Greenberg,et al. Specific adoptive therapy of established leukemia with syngeneic lymphocytes sequentially immunized in vivo and in vitro and nonspecifically expanded by culture with Interleukin 2. , 1981, Journal of immunology.
[70] D. Mathisen,et al. The in vivo distribution of autologous human and murine lymphoid cells grown in T cell growth factor (TCGF): implications for the adoptive immunotherapy of tumors. , 1980, Journal of immunology.
[71] S. Rosenberg,et al. In vitro growth of murine T cells. IV. Use of T-cell growth factor to clone lymphoid cells. , 1980, Cellular immunology.
[72] S. Rosenberg,et al. In vitro growth of murine T cells. V. The isolation and growth of lymphoid cells infiltrating syngeneic solid tumors. , 1980, Journal of immunology.
[73] S. Rosenberg,et al. In vitro growth of cytotoxic human lymphocytes. II. Use of T cell growth factor (TCGF) to clone human T cells. , 1980, Journal of immunology.
[74] D. Mathisen,et al. Comparison of in vivo cell distribution following either intraperitoneal or intravenous injection of lymphoid cells. , 1980, Transplantation.
[75] S. Rosenberg,et al. In vitro growth of murine T cells. III. Method for separation of T cell growth factor (TCGF) from concanavalin A and biological activity of the resulting TCGF. , 1980, Journal of immunological methods.
[76] H. Wigzell,et al. Long term growth in vitro of human T cell blasts with maintenance of specificity and function. , 1979, Journal of immunology.
[77] K. Smith,et al. Monoclonal cytolytic T-cell lines , 1979, The Journal of experimental medicine.
[78] S. Rosenberg,et al. In vitro growth of murine T cells. II. Growth of in vitro sensitized cells cytotoxic for alloantigens. , 1978, Journal of immunology.
[79] S. Rosenberg,et al. In vitro growth of murine T cells. I. Production of factors necessary for T cell growth. , 1978, Journal of immunology.
[80] S. Rosenberg,et al. In vitro growth of cytotoxic human lymphocytes. I. Growth of cells sensitized in vitro to alloantigens. , 1978, Journal of immunology.
[81] K. Smith,et al. Long-term culture of human antigen-specific cytotoxic T-cell lines , 1978, The Journal of experimental medicine.
[82] Kendall A. Smith,et al. Long term culture of tumour-specific cytotoxic T cells , 1977, Nature.
[83] S. Rosenberg,et al. Passive immunotherapy of cancer in animals and man. , 1977, Advances in cancer research.
[84] R. Gallo,et al. Selective in vitro growth of T lymphocytes from normal human bone marrows. , 1976, Science.
[85] N. Mitchison,et al. STUDIES ON THE IMMUNOLOGICAL RESPONSE TO FOREIGN TUMOR TRANSPLANTS IN THE MOUSE , 1955, The Journal of experimental medicine.